May 30, 2023
DEA Training Requirements
The passage of the MAT Act (2023) removed the X-Waiver requirement for buprenorphine prescribing and included…
May 24, 2023
Now Distributing Xylazine Test Strips
Xylazine, an animal tranquilizer that is toxic to humans, has made its way into the…
May 4, 2023
Spring 2023 Newsletter
April 28, 2023
NYS OASAS Xylazine Guidance
The New York State Office of Addiction Supports and Services (NYS OASAS) has released guidance…
March 30, 2023
FDA Approves Narcan as OTC Product
The U.S. Food and Drug Association (FDA) has approved Narcan's 4mg naloxone hydrochloride nasal spray…
February 1, 2023
Winter 2023 Newsletter
Thank you for reading our newsletter! We are proud to serve as a resource for…
January 13, 2023
X-Waiver: 2023 Updates
The passage of the MAT Act removed the requirement for DEA-licensed healthcare providers to undergo…
December 9, 2022
Xylazine: An emerging public health concern
Xylazine, an animal tranquilizer, is making its way into opioids and other substances in the…
October 14, 2022
